Markus Schwaiger - Selected Publications#

1. Schwaiger M, Schelbert HR, Ellison D, Hansen H, Yeatman L, Vinten-Johansen J, Selin C, Barrio J, Phelps ME: Sustained regional abnormalities in cardiac metabolism after transient ischemia in the chronic dog model. J Am Coll Cardiol. 1985;6(2):336-347.

2. Schwaiger M, Hutchins GD, Kalff V, Rosenspire K, Haka MS, Mallette S, Deeb GM, Abrams GD, Wieland DM: Evidence for regional catecholamine uptake and storage sites in the transplanted human heart by positron emission tomography.J Clin Invest. 1991;87(5):1681-1690.

3. Haubner R, Wester HJ, Senekowitsch-Schmidtke R, Diefenbach B, Kessler H, Stöcklin G, Schwaiger M: Radiolabeled v 3 integrin antagonists: A new class of tracers for tumor targeting. J Nuc Med. 1999;40(6):1061-1071.

4. Schömig A, Kastrati A, Dirschinger J, Mehilli J, Schricke U, Pache J, Martinoff S, Neumann FJ, Schwaiger M: Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. N Engl J Med. 2000;343(6):385-391.

5. Bengel FM, Ueberfuhr P, Schiepel N, Nekolla SG, Reichart B, Schwaiger M: Effect of sympathetic reinnervation on cardiac performance after heart transplantation. N Engl J Med. 2001;345(10):731-738.

6. Schömig A, Mehilli J, Antoniucci D, Ndrepepa G, Markwardt C, Di Pede F, Nekolla SG, Schlotterbeck K, Schühlen H, Pache J, Seyfarth M, Martinoff S, Benzer W, Schmitt C, Dirschinger J, Schwaiger M, Kastrati A (beyond 12 hours reperfusion alternative evaluation – BRAVE-2 – trial investigators): Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: A randomized controlled trial. JAMA. 2005;293(23):2865-2872.

7. Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, Lorenzen S, Schuster T, Wieder H, Herrmann K, Bredenkamp R, Höfler H, Fink U, Peschel C, Schwaiger M, Siewert JR: PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase trial. Lancet Oncol. 2007;8(9):797-805.

8. Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, Kübler H, Haberkorn U, Eisenhut M, Wester HJ, Gschwend JE, Schwaiger M: Evaluation of hybrid 68Ga-PSMA-ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56(5):668-674.

9. Weissleder R, Schwaiger MC, Gambhir SS, Hricak H: Imaging approaches to optimize molecular therapies. Sci Transl Med. 2016;8(355):355ps16.

10. Christian Hundshammer, Miriam Braeuer, Christoph A Müller, Adam E Hansen, Mathias Schillmaier, Stephan Düwel, Benedikt Feuerecker, Steffen J Glaser, Axel Haase, Wilko Weichert, Katja Steiger, Jorge Cabello, Franz Schilling, Jan-Bernd Hövener, Andreas Kjær, Stephan G Nekolla, Markus Schwaiger. Simultaneous characterization of tumor cellularity and the Warburg effect with PET, MRI and hyperpolarized 13 C-MRSI. Theranostics. 2018;8(17):4765-4780. – IF 8.579